Immunotyping of single cells isolated from tumor tissues and immunohistochemistry (IHC) analysis revealed that Ascl2 markedly decreased the number of tumor-infiltrating CD8+ T cells, CD4+ T cells, and CD11C+ CD11B- DCs (Fig. 3D–H and Supplementary Fig. 4B–D), suggesting immune activation in the TME. Here, ASCL2 is linked to neoplasm.